Clinical trial NCT00588172: Genetic Variation in OCT1 and Response to Metformin
Official title: Genetic Variation in OCT1 and Response to Metformin
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Type 2 Diabetes
Keywords: Metformin
Type 2 diabetes
Oct1
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2008-01-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Type 2 diabetes its microvascular and macrovascular complications have become a major global health problem. Metformin is often used as first-line therapy for this disorder given that it is cheap, may cause weight loss and does not have significant side-effects in healthy patients. On the other hand, as many as one third of all patients with type 2 diabetes initially treated with metformin never achieve a meaningful response to this intervention. Recently, genetic variation in the organic cation transporter 1 (Oct1) gene which encodes a protein, OCT1, mediating metformin uptake by the liver, its primary site of action, has been shown alter metformin action. In Oct1-deficient mice the glucose-lowering effects of metformin are completely abolished. Moreover a polymorphism with a 20% minor allele frequency in Caucasians also alters the effect of metformin on glucose tolerance (the net result of glucose uptake and glucose release) after ingestion of 75g of glucose. However, it is unknown if this polymorphism affects suppression of endogenous glucose production or stimulation of peripheral glucose uptake by metformin, or both, and to what degree. We propose to utilize established methodology to measure glucose turnover in response to a mixed meal to determine how common genetic variation in OCT1 alters response to metformin in healthy volunteers. This will clarify the effect of these variants on response to metformin in humans. The knowledge gained from this study will help to design future studies examining the role of OCT1 genotype in determining initial therapy for type 2 diabetes.


Eligibility criteria: Inclusion criteria: -

1. Heterozygous or homozygous for the nsSNPs R61C, G401S, 420Del, G465R, G174S (see supplementary info (3)) or without any nsSNPs that could potentially alter gene function.
2. Age 18 - 40.
3. Willingness to participate in this study.

Exclusion criteria: -

1. Fasting glucose \> 100mg/dL on one occasion.
2. Use of medication other than stable thyroid hormone replacement or oral contraception.
3. Subjects must not be pregnant or \< 6 months postpartum at the time of study.
4. Prior abdominal surgery other than hysterectomy, appendectomy or tubal ligation.

Primary outcomes:
measure: Change in glucose area under the curve after a mixed meal in response to metformin
timeFrame: before and after 1 week of metformin
Secondary outcomes:
measure: Change in glucose disappearance and suppression of endogenous glucose production in response to metformin
timeFrame: before and after 1 week of metformin therapy
Other outcomes:
Locations:
Study officials:
affiliation: Mayo Clinic
name: Adrian Vella, MD
role: PRINCIPAL_INVESTIGATOR
References: